These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 22342626)
1. Substituted azaquinazolinones as modulators of GHSr-1a for the treatment of type II diabetes and obesity. Hanrahan P; Bell J; Bottomley G; Bradley S; Clarke P; Curtis E; Davis S; Dawson G; Horswill J; Keily J; Moore G; Rasamison C; Bloxham J Bioorg Med Chem Lett; 2012 Mar; 22(6):2271-8. PubMed ID: 22342626 [TBL] [Abstract][Full Text] [Related]
2. Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. Rudolph J; Esler WP; O'connor S; Coish PD; Wickens PL; Brands M; Bierer DE; Bloomquist BT; Bondar G; Chen L; Chuang CY; Claus TH; Fathi Z; Fu W; Khire UR; Kristie JA; Liu XG; Lowe DB; McClure AC; Michels M; Ortiz AA; Ramsden PD; Schoenleber RW; Shelekhin TE; Vakalopoulos A; Tang W; Wang L; Yi L; Gardell SJ; Livingston JN; Sweet LJ; Bullock WH J Med Chem; 2007 Oct; 50(21):5202-16. PubMed ID: 17887659 [TBL] [Abstract][Full Text] [Related]
3. Ghrelin receptor inverse agonists as a novel therapeutic approach against obesity-related metabolic disease. Abegg K; Bernasconi L; Hutter M; Whiting L; Pietra C; Giuliano C; Lutz TA; Riediger T Diabetes Obes Metab; 2017 Dec; 19(12):1740-1750. PubMed ID: 28544245 [TBL] [Abstract][Full Text] [Related]
5. Identification of piperazine-bisamide GHSR antagonists for the treatment of obesity. Yu M; Lizarzaburu M; Beckmann H; Connors R; Dai K; Haller K; Li C; Liang L; Lindstrom M; Ma J; Motani A; Wanska M; Zhang A; Li L; Medina JC Bioorg Med Chem Lett; 2010 Mar; 20(5):1758-62. PubMed ID: 20137933 [TBL] [Abstract][Full Text] [Related]
7. Potent achiral agonists of the growth hormone secretagogue (ghrelin) receptor. Part 2: Lead optimisation. Witherington J; Abberley L; Briggs MA; Collis K; Dean DK; Gaiba A; King NP; Kraus H; Shuker N; Steadman JG; Takle AK; Sanger G; Wadsworth G; Butler S; McKay F; Muir A; Winborn K; Heightman TD Bioorg Med Chem Lett; 2008 Mar; 18(6):2203-5. PubMed ID: 18316188 [TBL] [Abstract][Full Text] [Related]
8. Discovery and optimization of novel 4-[(aminocarbonyl)amino]-N-[4-(2-aminoethyl)phenyl]benzenesulfonamide ghrelin receptor antagonists. Pasternak A; Goble SD; deJesus RK; Hreniuk DL; Chung CC; Tota MR; Mazur P; Feighner SD; Howard AD; Mills SG; Yang L Bioorg Med Chem Lett; 2009 Nov; 19(21):6237-40. PubMed ID: 19767208 [TBL] [Abstract][Full Text] [Related]
9. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. Feng J; Zhang Z; Wallace MB; Stafford JA; Kaldor SW; Kassel DB; Navre M; Shi L; Skene RJ; Asakawa T; Takeuchi K; Xu R; Webb DR; Gwaltney SL J Med Chem; 2007 May; 50(10):2297-300. PubMed ID: 17441705 [TBL] [Abstract][Full Text] [Related]
10. Discovery of a series of phosphonic acid-containing thiazoles and orally bioavailable diamide prodrugs that lower glucose in diabetic animals through inhibition of fructose-1,6-bisphosphatase. Dang Q; Liu Y; Cashion DK; Kasibhatla SR; Jiang T; Taplin F; Jacintho JD; Li H; Sun Z; Fan Y; DaRe J; Tian F; Li W; Gibson T; Lemus R; van Poelje PD; Potter SC; Erion MD J Med Chem; 2011 Jan; 54(1):153-65. PubMed ID: 21126019 [TBL] [Abstract][Full Text] [Related]
11. The design and synthesis of novel, potent and orally bioavailable N-aryl piperazine-1-carboxamide CCR2 antagonists with very high hERG selectivity. Cumming JG; Bower JF; Waterson D; Faull A; Poyser PJ; Turner P; McDermott B; Campbell AD; Hudson J; James M; Winter J; Wood C Bioorg Med Chem Lett; 2012 Jun; 22(12):3895-9. PubMed ID: 22608963 [TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity. Liu KK; Cornelius P; Patterson TA; Zeng Y; Santucci S; Tomlinson E; Gibbons C; Maurer TS; Marala R; Brown J; Kong JX; Lee E; Werner W; Wenzel Z; Vage C Bioorg Med Chem Lett; 2010 Jan; 20(1):266-71. PubMed ID: 19914063 [TBL] [Abstract][Full Text] [Related]
13. Discovery of a new class of ghrelin receptor antagonists. Mihalic JT; Kim YJ; Lizarzaburu M; Chen X; Deignan J; Wanska M; Yu M; Fu J; Chen X; Zhang A; Connors R; Liang L; Lindstrom M; Ma J; Tang L; Dai K; Li L Bioorg Med Chem Lett; 2012 Mar; 22(5):2046-51. PubMed ID: 22305493 [TBL] [Abstract][Full Text] [Related]
14. Identification of diaryl ether-based ligands for estrogen-related receptor α as potential antidiabetic agents. Patch RJ; Searle LL; Kim AJ; De D; Zhu X; Askari HB; O'Neill JC; Abad MC; Rentzeperis D; Liu J; Kemmerer M; Lin L; Kasturi J; Geisler JG; Lenhard JM; Player MR; Gaul MD J Med Chem; 2011 Feb; 54(3):788-808. PubMed ID: 21218783 [TBL] [Abstract][Full Text] [Related]
15. Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. Li JJ; Nahra J; Johnson AR; Bunker A; O'Brien P; Yue WS; Ortwine DF; Man CF; Baragi V; Kilgore K; Dyer RD; Han HK J Med Chem; 2008 Feb; 51(4):835-41. PubMed ID: 18251495 [TBL] [Abstract][Full Text] [Related]
16. New beta-alanine derivatives are orally available glucagon receptor antagonists. Lau J; Behrens C; Sidelmann UG; Knudsen LB; Lundt B; Sams C; Ynddal L; Brand CL; Pridal L; Ling A; Kiel D; Plewe M; Shi S; Madsen P J Med Chem; 2007 Jan; 50(1):113-28. PubMed ID: 17201415 [TBL] [Abstract][Full Text] [Related]
18. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Nomura S; Sakamaki S; Hongu M; Kawanishi E; Koga Y; Sakamoto T; Yamamoto Y; Ueta K; Kimata H; Nakayama K; Tsuda-Tsukimoto M J Med Chem; 2010 Sep; 53(17):6355-60. PubMed ID: 20690635 [TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists. Sasaki S; Kitamura S; Negoro N; Suzuki M; Tsujihata Y; Suzuki N; Santou T; Kanzaki N; Harada M; Tanaka Y; Kobayashi M; Tada N; Funami M; Tanaka T; Yamamoto Y; Fukatsu K; Yasuma T; Momose Y J Med Chem; 2011 Mar; 54(5):1365-78. PubMed ID: 21319751 [TBL] [Abstract][Full Text] [Related]
20. The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitus. Pfefferkorn JA; Tu M; Filipski KJ; Guzman-Perez A; Bian J; Aspnes GE; Sammons MF; Song W; Li JC; Jones CS; Patel L; Rasmusson T; Zeng D; Karki K; Hamilton M; Hank R; Atkinson K; Litchfield J; Aiello R; Baker L; Barucci N; Bourassa P; Bourbonais F; D'Aquila T; Derksen DR; MacDougall M; Robertson A Bioorg Med Chem Lett; 2012 Dec; 22(23):7100-5. PubMed ID: 23089526 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]